Changing the Titular or Representative in Colombia

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Changing the certificate holder, changing the legal representative, or cancelling and reapplying – all three routes work in Colombia, but their costs differ sharply. Changing the titular is a change of legal nature with an official fee of COP 826,546; changing the apoderado only requires reissuing the power of attorney under Art. 29 and updating the contact information in SIRIS, with no change fee; cancelling and reapplying means paying the registration fee again – 321.91 UVB ≈ COP 3,898,330 for class I/IIa, 364.36 UVB ≈ COP 4,413,000 for class IIb/III – and waiting for review all over again.

GRZAN’s assessment is that if a representative can be changed, do not change the holder; if a change can be filed, do not cancel. The cost of changing the representative concentrates in documents; the cost of changing the holder concentrates in review; the cost of cancelling and starting over falls on time and market absence – automatic registration takes 2 business days and standard registration 90 business days, excluding the round trips of deficiency responses and the rework of the dossier.

2. Legal basis

RegulationNumberPublication dateProvision
Decreto 4725 de 2005 (medical device registration and vigilance system)Decreto 4725 de 2005December 26, 2005Art. 3 (definition of titular)
Decreto 4725 de 2005 (medical device registration and vigilance system)Decreto 4725 de 2005December 26, 2005Art. 19 (legal documentation list)
Decreto 4725 de 2005 (medical device registration and vigilance system)Decreto 4725 de 2005December 26, 2005Art. 20 (certificate must state the name and address of the titular)
Decreto 4725 de 2005 (medical device registration and vigilance system)Decreto 4725 de 2005December 26, 2005Art. 29 (power of attorney, POA)
Decreto 582 de 2017 (amends 4725/2005)Decreto 582 de 2017April 4, 2017Change, renewal, post-grant verification and suspension/cancellation rules
Ley 1437 de 2011 (CPACA)Ley 1437 de 20112011Correction, cancellation and resumption of administrative acts
Resolución 2025067543 (2026 fee schedule)Resolución 2025067543December 22, 2025Change of legal nature COP 826,546; registration fees COP 3,898,330 / COP 4,413,000
Ley 962 de 2005 (anti-bureaucracy law)Ley 962 de 20052005Article 57 (follow-up control within 15 days after issuance)

3. Expert insights

#### Changing the representative is the lightest action; changing the holder is the heaviest

The apoderado is the agent of the titular, so changing the agent does not touch the registered entity; in essence it is a document update. Changing the titular alters the right-holder that the administrative act points to; it is a change of legal nature with an official fee of COP 826,546 and requires legal documents issued by both parties. When structuring engagements for clients, GRZAN places the variable elements at the representative level and fixes the registered entity.

#### Cancellation is not a free exit: the certificate is gone, the market is still there

Cancellation terminates the effect of the registration certificate, but products already placed on the market remain subject to vigilance duties; the 72-hour serious adverse event reporting and quarterly periodic reports of Resolución 4816 de 2008 are not automatically waived by cancellation. If no successor entity and stock disposal plan are arranged before cancellation, the market carries a long period of certified-goods-without-certificate status, a high-risk scenario in verification.

#### The real cost of reapplying is time and channels, not just the fee

Reapplying requires paying COP 3,898,330 or COP 4,413,000 again, but what is more expensive is the gap: distribution channels interrupted, tender qualifications lost, and completed market access work rendered void. In a market that depends on imports for roughly 80%–85% of its supply, the out-of-stock period is usually filled by competitors. GRZAN’s advice is to treat the renewal window as a hard calendar item – at least 3 months before device expiry and within 6 months before IVD expiry.

#### The regime is being rewritten, so entity structures should keep flexibility

The MSPS draft decree Régimen Sanitario de Dispositivos Médicos was published for comment in January 2026 (about 16 chapters and 180 articles), notified to the WTO on May 18, 2026 with comments closing July 17, 2026; directions include a three-tier authorization system, validity changed to indefinite and linked to post-market performance, and a self-proposed 18-month transition period. As of the verification date it has not been signed or promulgated, and Decreto 4725/2005 and Decreto 3770/2004 remain in force. GRZAN’s judgment: do not write current entity arrangements so rigidly that they cannot migrate; leave a transferable path.

4. Practical recommendations

  1. Manufacturer legal counsel: prefer changing the apoderado, reissuing the power of attorney under Art. 29 with the Spanish translation completed.
  2. GRZAN regulatory team: where the titular genuinely must change, obtain the corporate documents of both parties first, then file the change of legal nature with a budget of COP 826,546.
  3. Registration specialist: after any change, immediately verify that the titular field on the certificate and the SIRIS contact information have both been updated.
  4. Project management: set renewal windows as hard calendar items – 3 months before device expiry and within 6 months before IVD expiry.
  5. Vigilance lead: before cancellation, secure a successor for the vigilance duties on stock and in-use products and keep the 72-hour reporting chain alive.
  6. Corporate planning lead: track the progress of the Proyecto de Decreto and assess the impact of the 18-month transition period on existing entity arrangements.

5. Verification checklist

  • □ The change type is confirmed: representative change, entity change, or cancel and reapply
  • □ The new POA for a representative change has been issued under Art. 29 with the Spanish translation completed
  • □ The entity change budget includes the change of legal nature at COP 826,546
  • □ The reapplication budget includes COP 3,898,330 (I/IIa) or COP 4,413,000 (IIb/III)
  • □ After the change, the titular field on the certificate and the SIRIS information are synchronized
  • □ Renewal windows are scheduled: devices 3 months, IVDs within 6 months
  • □ The vigilance successor and stock disposal plan are in place before cancellation
  • □ The signing status and transition arrangements of the Proyecto de Decreto are being tracked
  • GRZAN regulatory team

Regulatory information verified as of October 29, 2026

All conclusions published here are based on the current regulatory texts issued by the competent authority and are verified item by item before delivery.

GRZAN manages holder and representative changes for manufacturers in the Colombian market, from POA reissuance to changes of legal nature and renewal scheduling, and provides local licensed-entity and importer support with complete fee budgeting. To plan a change without losing your certificate or your market window, contact us at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail